Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)

Affiliations

• ¹ Oregon Health & Science University, Portland, OR, USA. simpsone@ohsu.edu.
• ² Westmead Hospital, Sydney Medical School, The University of Sydney, Sydney, Australia.
• ³ National Expertise Center of Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
• ⁴ Northwestern University, Chicago, IL, USA.
• ⁵ National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
• ⁶ Henri Mondor University Hospital and Université Paris‑Est Créteil University, Créteil, France.
• ⁷ Almirall, S.A., Barcelona, Spain.
• ⁸ Eli Lilly and Company, Indianapolis, IN, USA.
• ⁹ University Hospital Bonn, Bonn, Germany.